Stock Market Watch

Five Penny Stocks with Heavy Volume to Watch for Monday

by ·


RXI Pharmaceuticals (OTC:RXII) traded as high as $.20 during Friday’s trading session and last traded at $.15 for a gain of 15.38% from Thursday’s close… RXII shares have traded as high as $.20 over the past 52 weeks, which is 0% off that high at last traded stock price. Get my next ALERT 100% FREE

RXi Pharmaceuticals Corporation is a biotechnology company focused on discovering, developing and commercializing innovative therapies based on its proprietary, next-generation RNAi platform.

Oryon Technologies Inc (PINK:ORYN) traded as high as $1.24 during Friday’s trading session and last traded at $1.20 for a gain of 7.14% from Thursday’s close… ORYN shares have traded as high as $1.21 over the past 52 weeks, which is .83% off that high at last traded stock price.


Oryon Technologies, formerly Oryon Holdings, is an exploration-stage company engaged in the exploration of mineral properties for gold. The Company purchased a 100% interest in the Tabuk Gold property, which consists of a prospect that contains one seven-unit claim block containing 955.2 hectares.

RarusTechnologies (PINK:RARS) traded as high as $.35 during Friday’s trading session and last traded at $.183 for a loss of 48.61% from Thursday’s close… RARS shares have traded as high as $.59 over the past 52 weeks, which is 68.98% off that high at last traded stock price.

Rarus Minerals, Inc., an exploration stage corporation, engages in the acquisition, exploration, and development of rare earth mineral properties.

PolyMedix, Inc. (OTC:PYMX) traded as high as $.405 during Friday’s trading session and last traded at $.355 for a loss of 39.32% from Thursday’s close… PYMX shares have traded as high as $1.50 over the past 52 weeks, which is 76.33% off that high at last traded stock price. Get my next ALERT 100% FREE

PolyMedix is a clinical stage biotechnology company developing first-in-class, small-molecule drugs for the treatment of serious acute care conditions. PolyMedix has two lead compounds and a pipeline of innovative infectious disease and cardiovascular product candidates, all of which were internally developed using a proprietary drug discovery technology platform.

Sefe Incorporated (OTC:SEFE) traded as high as $.905 during Friday’s trading session and last traded at $.73 for a loss of 18.44% from Thursday’s close… SEFE shares have traded as high as $2.96 over the past 52 weeks, which is 75.34% off that high at last traded stock price.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership.

 

More Posts by this author

Post Written By: Oliver Crowne

Oliver Crowne is the main editor for http://www.StockPreacher.com


Ed Liston

Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications. He is widely quoted in various financial publications on the Internet. When Ed is not writing about stocks, investing in stocks, talking about stocks, or otherwise doing something stock related, he likes to go sailing and fishing.

You may also like...